Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 650 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $620.27, for a total value of $403,175.50. Following the sale, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Medpace Stock Performance
Shares of NASDAQ MEDP opened at $593.99 on Tuesday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a 50 day moving average price of $568.10 and a two-hundred day moving average price of $495.34. The stock has a market cap of $16.58 billion, a P/E ratio of 34.82, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on MEDP shares. Mizuho increased their price target on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and upped their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Royal Bank Of Canada increased their target price on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Finally, Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $584.18.
View Our Latest Report on MEDP
Institutional Investors Weigh In On Medpace
Several large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its holdings in Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares in the last quarter. BlackRock Inc. acquired a new stake in Medpace in the second quarter worth $1,323,047,000. AQR Capital Management LLC increased its stake in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Madison Asset Management LLC acquired a new position in shares of Medpace during the second quarter valued at about $128,956,000. Finally, Bank of America Corp DE acquired a new position in shares of Medpace during the second quarter valued at about $116,891,000. Institutional investors and hedge funds own 77.98% of the company's stock.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
